
---
title: '狂犬病药物治疗的研究进展'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=807031'
author: 科学网
comments: false
date: Fri, 12 Nov 2021 05:31:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=807031'
---

<div>   
<p style="text-autospace:ideograph-numeric;line-height:200%"><a name="OLE_LINK1" href="http://blog.sciencenet.cn/undefined"></a><span style="font-family: 楷体, 楷体_GB2312, SimKai;"><strong><span style="line-height: 200%; font-size: 29px;">狂犬病药物治疗的研究进展</span></strong></span></p><p style="margin-left:0;text-indent:43px;text-autospace:ideograph-numeric;line-height:200%"><span style="line-height: 200%; font-size: 19px; font-family: 楷体, 楷体_GB2312, SimKai;"> </span></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-family: 楷体, 楷体_GB2312, SimKai; font-size: 24px;"><strong><span style="font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; color: #FF0000;">狂犬病目前只能用疫苗预防，不能用药物治疗。</span></strong><strong><span style="font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; color: #FF0000;"></span></strong></span></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-family: 楷体, 楷体_GB2312, SimKai; font-size: 24px;"><strong><span style="font-family: SimSun; line-height: 200%; color: #FF0000; font-size: 21px;">迄今全球狂犬病治疗尚无一例获得公认的成功。</span></strong><span style="font-family: 楷体, 楷体_GB2312, SimKai; font-size: 24px; color: #0070C0;"><strong><span style="font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; font-size: 21px;">前些年曾报导的极个别成功案例后来都被否定了：蝙蝠引起的人狂犬病存在个别自愈的病例，与所采用的治疗方法无关，而由狗引发的人狂犬病迄今从无治愈或自愈的先例。</span></strong></span></span></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-family: 楷体, 楷体_GB2312, SimKai; font-size: 24px; color: #0070C0;"><strong><span style="color: #0070C0; font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; font-size: 21px;">在世界范围内人类对狂犬病治疗的研究从未停步。比利时和意大利的研究人员于11月3日在专业杂志《Annual Reports in Medic</span></strong><strong><em><span style="color: #0070C0; font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;">inal Chemistry</span></em></strong><strong><em><span style="color: #0070C0; font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;">（</span></em></strong><strong><span style="color: #0070C0; font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;">药物化学年度报告）</span></strong><strong><span style="color: #0070C0; font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; font-size: 21px;">》上发表综述论文（网上提前发布）：“</span></strong><strong><span style="color: #0070C0; font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;"> Which antivirals for the coming decade? </span></strong><strong><span style="color: #0070C0; font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;">（</span></strong><strong><span style="color: #0070C0; font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; letter-spacing: 0px; font-size: 21px; background: #FFFFFF;">未来10年将使用哪些抗病毒药物?）”（见参考文献），介绍了当前针对十多种常见病毒病（包括狂犬病）药物治疗的研究进展</span></strong><strong><span style="color: #0070C0; font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; font-size: 21px;">。</span></strong></span><span style="font-family: 楷体, 楷体_GB2312, SimKai; font-size: 24px;"><strong><span style="font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; font-size: 21px;"></span></strong><strong><span style="font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; font-size: 21px;"></span></strong></span></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-family: 楷体, 楷体_GB2312, SimKai; font-size: 24px;"><strong><span style="font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; color: #C00000; font-size: 21px;">目前对狂犬病的化学药物治疗在体外试验中已筛选到一些很有希望的药物，然而在体内的动物试验和人类临床试验中都尚未取得成功</span></strong><strong><span style="font-family: 楷体, 楷体_GB2312, SimKai; line-height: 200%; font-size: 21px;">。</span></strong></span><span style="font-family: 楷体, 楷体_GB2312, SimKai;"><strong><span style="line-height: 200%; font-size: 21px;"></span></strong><strong><span style="line-height: 200%; font-size: 21px;"></span></strong><strong><span style="line-height: 200%; font-size: 21px;"></span></strong></span></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: SimSun;line-height: 200%;font-size: 21px"> </span></strong></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: SimSun;line-height: 200%;color: #C00000;font-size: 21px">以下是该综述论文中有关狂犬病药物治疗的研究进展的简介：</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 宋体, SimSun;"><strong><span style="text-decoration: underline; line-height: 200%; font-size: 19px;">狂犬病毒(</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #C00000; font-size: 19px;">RABV</span></strong><strong><span style="text-decoration: underline; line-height: 200%; font-size: 19px;">)</span></strong><span style="line-height: 200%; font-size: 19px;">是</span><strong><span style="text-decoration: underline; line-height: 200%; font-size: 19px;">弹状病毒科</span></strong><strong><span style="text-decoration: underline; line-height: 200%; font-size: 19px;">(Rhabdoviridae)</span></strong><strong><span style="text-decoration: underline; line-height: 200%; font-size: 19px;">丽沙病毒属（</span></strong><strong><span style="text-decoration: underline; line-height: 200%; font-size: 19px;">Lyssavirus</span></strong><span style="line-height: 200%; font-size: 19px;">）的原型种，这是一组携带反义单链</span><strong><span style="line-height: 200%; color: #C00000; font-size: 19px;">RNA</span></strong><span style="line-height: 200%; font-size: 19px;">基因组的嗜神经病毒，可感染人类和哺乳动物。狂犬病是所有病毒感染中最致命的，在出现临床症状后死亡率为100%。RABV进入周围神经后，通过轴突运输到达中枢神经系统（CNS），在那里优先复制，避开宿主免疫系统，导致严重的、无法治愈的神经疾病。</span></span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 宋体, SimSun;"><span style="font-family: AdvP800D; line-height: 200%; font-size: 19px;">有效的疫苗可用于</span><span style="text-decoration: underline; font-family: AdvP800D; line-height: 200%; font-size: 19px;">暴露前预防（PreP</span><span style="font-family: AdvP800D; line-height: 200%; font-size: 19px;">)，</span><span style="text-decoration: underline; font-family: AdvP800D; line-height: 200%; font-size: 19px;"><span style="font-family: AdvP800D;">人类狂犬病免疫球蛋白</span><a name="OLE_LINK4" href="http://blog.sciencenet.cn/undefined"></a>(HRIG)</span><span style="font-family: AdvP800D; line-height: 200%; font-size: 19px;">可用于感染后早期</span><span style="text-decoration: underline; font-family: AdvP800D; line-height: 200%; font-size: 19px;"><span style="font-family: AdvP800D;">暴露后预防</span>(PEP</span><span style="font-family: AdvP800D; line-height: 200%; font-size: 19px;">)干预，可成功防止疾病发展为出现<span style="font-family: AdvP800D;">症状。然而，由于高危国家常规免疫覆盖率低，感染狂犬病的风险仍然存在，全世界每年估计有</span>59，000人死于RABV。</span></span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="line-height: 200%; font-size: 19px; font-family: 宋体, SimSun;"><span style="line-height: 200%; font-size: 19px; font-family: AdvP800D;">由于</span>RABV的人畜共患病传播，预计RABV将在全球持续作为普遍的公共卫生威胁而存在相当长的时间。<span style="line-height: 200%; font-size: 19px; font-family: AdvP800D;">在约</span>99%的病例中，这种传播是通过受感染狗咬伤后的传染性唾液传播的。在脑炎性狂犬病的症状期，抗病毒分子可能能够抑制病毒在受感染者体内的复制，这将是对抗人类RABV感染的下一个主要步骤，但是直接在脑脊液中给药仍被认为是一个尚未解决的挑战。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 宋体, SimSun;"><span style="font-family: AdvP800D; line-height: 200%; font-size: 19px;">开发抗病毒化合物也是有价值<span style="font-family: AdvP800D;">的，因为它是目前用于</span>PEP的狂犬病免疫球蛋白</span><span style="text-decoration: underline; font-family: AdvP800D; line-height: 200%; font-size: 19px;">(RIG)</span><span style="font-family: AdvP800D; line-height: 200%; font-size: 19px;">的具有<span style="font-family: AdvP800D;">成本效益和易于储存的替代品，特别是考虑到</span>RABV预防相关的沉重经济负担，以及大多数感染(95%)发生在非洲和亚洲，这些地区的生物制品供应有限。</span></span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 宋体, SimSun;"><strong><span style="line-height: 200%; color: #0070C0; font-size: 19px;">广谱RNA聚合酶抑制剂</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #0070C0; font-size: 19px;">利巴韦林</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #0070C0; font-size: 19px;">（</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #0070C0; font-size: 19px;">ribavirin</span></strong><strong><span style="line-height: 200%; color: #0070C0; font-size: 19px;">）</span></strong><strong><span style="line-height: 200%; color: #0070C0; font-size: 19px;">对RABV</span></strong><strong><span style="line-height: 200%; color: #0070C0; font-size: 19px;">表现出很有希望的</span></strong><strong><span style="line-height: 200%; color: #0070C0; font-size: 19px;">体外抑制活性</span></strong><strong><span style="line-height: 200%; color: #0070C0; font-size: 19px;">，然而</span></strong><strong><span style="line-height: 200%; color: #0070C0; font-size: 19px;">在临床前动物模型和人体临床试验中</span></strong><strong><span style="line-height: 200%; color: #0070C0; font-size: 19px;">却都</span></strong><strong><span style="line-height: 200%; color: #0070C0; font-size: 19px;">并没有转化为体内抗病毒疗效</span></strong><span style="line-height: 200%; font-size: 19px;">。与</span><span style="text-decoration: underline; line-height: 200%; font-size: 19px;">利巴韦林</span><span style="line-height: 200%; font-size: 19px;">相比，一些名为EICAR和EICNR的</span><span style="text-decoration: underline; line-height: 200%; font-size: 19px;">利巴韦林类似物</span><span style="line-height: 200%; font-size: 19px;">作为病毒复制和转录的抑制剂，在体外表现出更高的活性，最有可能通过IMPDH发挥抑制作用;然而，需要更系统的评价来确定它们的抗RABV潜力</span></span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="line-height: 200%; font-size: 19px; font-family: 宋体, SimSun;">独立研究表明，</span><span style="font-family: 宋体, SimSun;"><span style="line-height: 200%; font-size: 19px; font-family: 宋体, SimSun;"><a name="OLE_LINK2" href="http://blog.sciencenet.cn/undefined"></a></span><strong><span style="text-decoration: underline; line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: SimSun;">法匹拉韦</span></strong><strong><span style="text-decoration: underline; line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: SimSun;">（</span></strong><strong><span style="text-decoration: underline; font-family: AdvP800D; line-height: 200%; font-size: 19px;">favipiravir</span></strong><strong><span style="text-decoration: underline; font-family: AdvP800D; line-height: 200%; font-size: 19px;">）</span></strong><span style="font-family: AdvP800D; line-height: 200%; font-size: 19px;">在体外具有<span style="font-family: AdvP800D;">有效减少</span>RABV复制的能力;然而，在感染RABV的小鼠模型中，几乎或完全没有观察到该药对小鼠存活率的影响。</span></span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 宋体, SimSun;"><span style="font-family: AdvP800D; line-height: 200%; font-size: 19px;"><span style="font-family: AdvP800D;">最近，体内成像研究表明，小鼠肌肉注射</span>RABV后1小时或2天使用</span><span style="font-family: 宋体, SimSun; text-decoration: underline;"><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: SimSun;">法匹拉韦（</span><span style="font-family: AdvP800D; line-height: 200%; font-size: 19px;">favipiravir）</span></span><span style="font-family: AdvP800D; line-height: 200%; font-size: 19px;">可以抑制病毒在外周系统的复制，但需要双倍或三倍剂量才能抑制<span style="font-family: AdvP800D;">病毒在中枢神经系统（</span>CNS）中的复制。</span></span></p><h1 style="margin-top:0;margin-right:0;margin-bottom:13px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:200%;background:rgb(255,255,255)"><span style="font-family: 宋体, SimSun;"><span style="line-height: 200%; font-size: 19px;">两种金刚烷衍生物，</span><span style="text-decoration: underline; line-height: 200%; font-size: 19px;">1-金刚烷-(5-溴-2-甲氧基苄基)胺(ABMA</span><span style="line-height: 200%; font-size: 19px;">)及其1-二甲基类似物DABMA，通过干扰晚期</span><span style="text-decoration: underline; line-height: 200%; font-size: 19px;">细胞核内体（</span><span style="text-decoration: underline; line-height: 200%; letter-spacing: 0px; font-size: 19px;">endosomal</span><span style="line-height: 200%; font-size: 19px;">）途径的不同步骤来阻止RABV病毒的基因表达和基因组复制。如在感染前2小时用药，这些早期阶段进入的抑制剂在体外表现出抗RABV的微摩尔（micromolar）活性。</span></span></h1><h1 style="margin-top:0;margin-right:0;margin-bottom:13px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:200%;background:rgb(255,255,255)"><span style="font-family: 宋体, SimSun;"><span style="line-height: 200%; font-size: 19px;">最近，基于单周期RABV报告株的</span><span style="text-decoration: underline; line-height: 200%; font-size: 19px;">高通量筛选(HTS</span><span style="line-height: 200%; font-size: 19px;">)方案的实施，使之能够识别出一种顶级的、高效的和选择性RABV小分子抑制剂，命名为GRP-60367(图9中的化合物35)。机制鉴定表明，GRP-60367通过特异性靶向G蛋白上一个以前未知的药物敏感位点来阻断RABV的进入，这代表了一种适合于设计下一代RABV治疗和预防的抗病毒药物的先导化合物。</span></span></h1><p><strong><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=807031" title alt="image.png" width="725" height="425" style="width: 725px; height: 425px;" referrerpolicy="no-referrer"><br></span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">图9</span></strong><strong><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">.   </span></strong><strong><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">抗</span></strong><strong><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">狂犬病</span></strong><strong><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">毒（</span></strong><strong><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">RABV</span></strong><strong><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">）和麻疹病毒</span></strong><strong><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">感染的小分子。</span></strong><br></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px"> </span></p><p style="margin-top:0;margin-right:0;margin-bottom:0;margin-left:0;text-indent:43px;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:200%"><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">值得注意的是，一种特别保守的</span><span style="text-decoration: underline; font-family: AdvP800D; line-height: 200%; font-size: 19px;"><span style="font-family:AdvP800D">自由基</span>s -腺苷- l-甲硫氨酸(SAM)酶</span><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">被称为</span><span style="text-decoration:underline;"><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: SimSun;">蝰蛇毒素</span><span style="font-family: SimSun;line-height: 200%;font-size: 19px">（</span><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">viperin</span></span><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">）<span style="font-family:AdvP800D">，它似乎与许多</span>RNA病毒<span style="font-family:AdvP800D">包括</span>RABV的复制抑制有关。最近，有证据表明该酶可合成一种广谱抗病毒核苷酸，即</span><span style="text-decoration: underline; font-family: AdvP800D; line-height: 200%; font-size: 19px;">30 -脱氧- 30,40 -二脱氢胞苷三磷酸(ddhCTP，</span><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px"><span style="font-family:AdvP800D">图</span>9中的</span><strong><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">化合物</span></strong><strong><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">36</span></strong><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">)，它通过</span><span style="text-decoration: underline; font-family: AdvP800D; line-height: 200%; font-size: 19px;">自由基（radical</span><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">）<span style="font-family:AdvP800D">机制催化</span>CTP的脱水。更进一步的研究表明，</span><span style="text-decoration:underline;"><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: SimSun;">蝰蛇毒素</span><span style="font-family: SimSun;line-height: 200%;font-size: 19px">（</span><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">viperin</span></span><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">）通过激活</span><span style="text-decoration: underline; font-family: AdvP800D; line-height: 200%; font-size: 19px;">蛋白质泛素化（ubiquitination</span><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">）机制的一个组成部分，进而降解对病毒复制至关重要的细胞和病毒蛋白质来发挥抗病毒作用。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: AdvP800D;line-height: 200%;font-size: 19px">到目前为止，在动物宿主中进行的<span style="font-family:AdvP800D">抗</span>RABV感染疗法还未取得成功。</span></p><p style="margin-left:0;text-indent:49px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: SimSun;line-height: 200%;font-size: 21px">参考文献：</span></strong></p><p style="line-height: 200%;"><a name="OLE_LINK3" href="http://blog.sciencenet.cn/undefined"></a><span style="font-family: Helvetica;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">Groaz E, De Clercq E, Herdewijn P. Anno</span><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: SimSun;">，</span><span style="font-family: Helvetica;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2021: Which antivirals for the coming decade?</span><span style="font-family: SimSun;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:SimSun">（未来</span><span style="font-family:Helvetica">10</span><span style="font-family:SimSun">年将使用哪种抗病毒药物</span><span style="font-family:Helvetica">?</span><span style="font-family:SimSun">）</span></span><span style="font-family: Helvetica;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> </span><strong><em><span style="font-family: Helvetica;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">Annual Reports in Medicinal Chemistry</span></em></strong><strong><em><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: SimSun;">（</span></em></strong><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: SimSun;">药物化学年度报告），</span><span style="font-family: Helvetica;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">03 Nov 2021. PMCID: PMC8563371.</span><span style="font-family: SimSun;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> </span><span style="font-family: Helvetica;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"></span><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563371/" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563371/</a>  <a href="https://dx.doi.org/10.1016/bs.armc.2021.09.004" target="_blank"><span style="text-decoration: underline; font-family: Helvetica; line-height: 200%; color: #000000; letter-spacing: 0px; font-size: 19px; background: #FFFFFF;"></span></a><span style="font-family: SimSun;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> </span><span style="font-family: Helvetica;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">[Epub ahead of print]</span><span style="line-height: 200%; letter-spacing: 0px; font-size: 19px; background: #FFFFFF; font-family: SimSun;">。</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-347754-1312039.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-347754-1312039.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1311735.html" target="_black">狂犬病再次暴露后应如何处置？</a><br>                    <!--大赛结束-->
                                        
  
</div>
            